Gaucher’s Disease - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Gaucher’s Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 14+ companies and 16+ pipeline drugs in Gaucher’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Gaucher’s Disease: Overview
Gaucher disease (GD) is an inborn error of metabolism that affects the recycling of cellular glycolipids. It is an autosomal recessive inherited disorder of metabolism. The major clinical symptoms of GD include enlargement of the liver and spleen (hepatosplenomegaly), low number of red blood cells (anemia), easy bruising, and bone disease (bone pain and fractures). The diagnosis of GD is based on clinical symptoms and laboratory testing. A diagnosis of Gaucher disease is suspected in individuals who have bone problems, enlarged liver and spleen (hepatosplenomegaly), changes in red blood cell levels, easy bleeding and bruising from low platlets or signs of nervous system problems. Treatment is individualized for each patient depending on the type of Gaucher disease. Enzyme replacement therapy (ERT) has proven effective for individuals with Gaucher disease type 1.
'Gaucher’s Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gaucher’s Disease pipeline landscape is provided which includes the disease overview and Gaucher’s Disease treatment guidelines. The assessment part of the report embraces, in depth Gaucher’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gaucher’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Gaucher’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gaucher’s Disease Emerging Drugs
Further product details are provided in the report……..
Gaucher’s Disease: Therapeutic Assessment
This segment of the report provides insights about the different Gaucher’s Disease drugs segregated based on following parameters that define the scope of the report, such as:
Gaucher’s Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Gaucher’s Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gaucher’s Disease drugs.
Gaucher’s Disease Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Gaucher’s Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 14+ companies and 16+ pipeline drugs in Gaucher’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Gaucher’s Disease: Overview
Gaucher disease (GD) is an inborn error of metabolism that affects the recycling of cellular glycolipids. It is an autosomal recessive inherited disorder of metabolism. The major clinical symptoms of GD include enlargement of the liver and spleen (hepatosplenomegaly), low number of red blood cells (anemia), easy bruising, and bone disease (bone pain and fractures). The diagnosis of GD is based on clinical symptoms and laboratory testing. A diagnosis of Gaucher disease is suspected in individuals who have bone problems, enlarged liver and spleen (hepatosplenomegaly), changes in red blood cell levels, easy bleeding and bruising from low platlets or signs of nervous system problems. Treatment is individualized for each patient depending on the type of Gaucher disease. Enzyme replacement therapy (ERT) has proven effective for individuals with Gaucher disease type 1.
'Gaucher’s Disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gaucher’s Disease pipeline landscape is provided which includes the disease overview and Gaucher’s Disease treatment guidelines. The assessment part of the report embraces, in depth Gaucher’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gaucher’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Gaucher’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Gaucher’s Disease.
This segment of the Gaucher’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gaucher’s Disease Emerging Drugs
- GPH301: Graphite Bio
- AVR-RD-02: AVROBIO
Further product details are provided in the report……..
Gaucher’s Disease: Therapeutic Assessment
This segment of the report provides insights about the different Gaucher’s Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Gaucher’s Disease
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Gaucher’s Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Gaucher’s Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gaucher’s Disease drugs.
Gaucher’s Disease Report Insights
- Gaucher’s Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Gaucher’s Disease drugs?
- How many Gaucher’s Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gaucher’s Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gaucher’s Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gaucher’s Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- CANbridge Life Sciences
- AVROBIO
- Gain Therapeutics
- M6P Therapeutics
- Denali Therapeutics
- Graphite Bio
- Sanofi
- Freeline Therapeutics
- Orphazyme
- Sanofi
- Prevail Therapeutics
- Yuhan
- CAN103
- AVR-RD-02
- GT-02287
- GT-02329
- M-011
- M-013
- ETV:GCase
- GPH 301
- Venglustat
- FLT 201
- Arimoclomol
- Eliglustat
- PR-001
- YHC-1116
Introduction
Executive Summary
Gaucher’s Disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Gaucher’s Disease – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Eliglustat: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Arimoclomol: Orphazyme
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
AVR-RD-02: AVROBIO
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
CAN103: CANbridge Life Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Gaucher’s Disease Key Companies
Gaucher’s Disease Key Products
Gaucher’s Disease- Unmet Needs
Gaucher’s Disease- Market Drivers and Barriers
Gaucher’s Disease- Future Perspectives and Conclusion
Gaucher’s Disease Analyst Views
Appendix
Executive Summary
Gaucher’s Disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Gaucher’s Disease – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Eliglustat: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Arimoclomol: Orphazyme
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
AVR-RD-02: AVROBIO
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
CAN103: CANbridge Life Sciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Gaucher’s Disease Key Companies
Gaucher’s Disease Key Products
Gaucher’s Disease- Unmet Needs
Gaucher’s Disease- Market Drivers and Barriers
Gaucher’s Disease- Future Perspectives and Conclusion
Gaucher’s Disease Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Gaucher’s Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Gaucher’s Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Gaucher’s Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Gaucher’s Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
